Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550165 | 1.00 | CSF1R (1.00) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL6996466 | 0.77 | KMT2A (0.61) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL11127257 | 0.76 | MAPT (0.61) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL13102148 | 0.75 | MEN1 (0.60) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL20670037 | 0.74 | MAPT (0.57) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL18122029 | 0.68 | ALDH1A1 (0.55) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL24796192 | 0.68 | MAPT (0.51) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL18774623 | 0.68 | ERCC5 (0.56) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL18121538 | 0.67 | ALDH1A1 (0.53) | CSF1RMAPTFLT3MEN1PDGFRB | |
| SCHEMBL17306394 | 0.67 | ALDH1A1 (0.53) | CSF1RMAPTFLT3MEN1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4715066-A1 | PANEL OF MICRORNAS AS BIOMARKERS OF NON-SEGMENTAL VITILIGO | Servicio Andaluz De Salud (ES) | 2026-03-25 | — | — | EP | disclosed |
| US-12534764-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | AROG PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250305063-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations | AROG PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12404555-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | AROG PHARMACEUTICALS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12383549-B2 | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders | AROG PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | AROG PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250078957-A1 | Unsupervised Machine Learning Methods | AMPEL BIOSOLUTIONS LLC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2023158713-A1 | UNSUPERVISED MACHINE LEARNING METHODS | AMPEL BIOSOLUTIONS, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023102379-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230128591-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2023-01-12 | — | — | US | disclosed |
| US-20220409610-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | AROG PHARMACEUTICALS, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11458131-B2 | Crenolanib for treating FLT3 mutated proliferative disorders | AROG PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11440880-B2 | Thalidomide analogs and methods of use | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220218694-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | AROG PHARMACEUTICALS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | CSF1R 1404/4885MAPT 3662/4885FLT3 2173/4885 |
| US-20250305063-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations | FLT3, RET, CSF1R | CSF1R 3/4885MAPT 4440/4885FLT3 1/4885 |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | FLT3, RET, MKI67 | CSF1R 12/4885MAPT 3372/4885FLT3 1/4885 |
| US-11458131-B2 | Crenolanib for treating FLT3 mutated proliferative disorders | FLT3, FLT1, RET | CSF1R 6/4885MAPT 2265/4885FLT3 1/4885 |
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | CSF1R 747/4885MAPT 1427/4885FLT3 1586/4885 |
| US-20230011378-A1 | Combination Therapy For Treatment Of Cancer | CDK9, KRAS, BRD9 | CSF1R 1274/4885MAPT 2260/4885FLT3 810/4885 |
| US-20230128591-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | CSF1R 12/4885MAPT 3372/4885FLT3 1/4885 |
| US-12404555-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | FLT3, RET, CSF1R | CSF1R 3/4885MAPT 4440/4885FLT3 1/4885 |
| US-12534764-B2 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations | FLT3, NUP188, KPNB1 | CSF1R 38/4885MAPT 3077/4885FLT3 1/4885 |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | CSF1R 12/4885MAPT 3372/4885FLT3 1/4885 |
| US-11440880-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CSF1R 796/4885MAPT 2830/4885FLT3 543/4885 |
| US-12383549-B2 | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders | CCAR2, BAX, TP53 | CSF1R 1851/4885MAPT 3306/4885FLT3 2042/4885 |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | CSF1R 1404/4885MAPT 3662/4885FLT3 2173/4885 |
| US-20220409610-A1 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | FLT3, FLT1, RET | CSF1R 6/4885MAPT 2265/4885FLT3 1/4885 |
| US-20220218694-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | FLT3, RUNX1, RET | CSF1R 8/4885MAPT 4354/4885FLT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.